SkinMedica, Inc. and New York University announced today that they have entered into a global license agreement to develop novel products to address skin hyperpigmentation based on technology invented at NYU.
"Our scientific discovery involves natural products that act by an entirely novel mechanism to modulate skin pigmentation," said Seth J. Orlow, M.D., Ph.D., Chair of the Ronald O. Perelman Department of Dermatology at NYU, and Director of the Program in Cutaneous Biology and NYU Langone Medical Center's Center of Excellence in Cancers of the Skin. "The treatment of hyperpigmentation remains a major unmet need, and we are especially pleased to partner with SkinMedica to advance new products to address this problem."
Under the terms of the agreement, SkinMedica has licensed exclusive rights to develop and market products based on the NYU technology, with a range of applications in the modulation of skin pigmentation.
"Dr. Orlow has a long history of innovation and invention in dermatology and skin biology, and we are proud to partner with him and NYU to deliver novel products for pigmentation," said Mary Fisher, SkinMedica President and CEO. "Hyperpigmentation is a very common problem worldwide, with limited treatment options. We look forward to advancing this program, which has enormous global market potential."
About Hyperpigmentation
Hyperpigmentation is a common condition in which patches of skin become darker in color than the surrounding skin. It can affect the skin color of people of any race. Normal skin color is formed by melanin, which is produced by special cells called melanocytes in the top layer of the skin. Uneven melanin production can occur in response to hormonal changes, and may also occur with certain diseases. Another common presentation is in response to skin damage or inflammation. It is advisable for persons with pigmentary problems to visit a dermatologist for a discussion of diagnosis and treatment options, and to rule out skin cancer.
For more information, visit www.skinmedica.com.
